Wells Fargo
SABS icon

Wells Fargo’s SAB Biotherapeutics SABS Stock Holding History

Wells Fargo’s Portfolio SABS Stock Details SABS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$172K Buy
+44,083
New +$164K ﹤0.01% 5285
2024
Q2 		– Sell
-61
Closed -$277 – 7382
2024
Q1 		$277 Buy
61
+32
+110% +$176 ﹤0.01% 6419
2023
Q4 		$202 Buy
29
+2
+7% +$17 ﹤0.01% 6610
2023
Q3 		$169 Buy
27
+2
+8% +$15 ﹤0.01% 6628
2023
Q2 		$205 Buy
25
+6
+32% +$49 ﹤0.01% 6694
2023
Q1 		$82 Hold
19
– – ﹤0.01% 6979
2022
Q4 		$109 Buy
19
+1
+6% +$9 ﹤0.01% 6771
2022
Q3 		$0 Buy
18
+1
+6% +$10 ﹤0.01% 7255
2022
Q2 		$0 Buy
+17
New +$357 ﹤0.01% 7384

Other funds holding SABS

CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Wells Fargo's SABS Position: Q2 2026 in Review

Wells Fargo opened a new position in SAB Biotherapeutics (SABS) in Q2 2026: 44,083 shares worth $172K. The stake represents ﹤0.01% of the portfolio and ranks #5285 among its holdings. This is a return to the name: Wells Fargo previously reported a position in SABS as recently as Q1 2024.

Wells Fargo first reported a position in SABS in Q2 2022 and has held it in 9 quarters since. 87 funds tracked by Wall St. Rank hold SABS as of Q2 2026.

  • Wells Fargo held 44,083 shares of SAB Biotherapeutics worth $172K as of Q2 2026.
  • SAB Biotherapeutics was a new Wells Fargo position in Q2 2026.
  • SAB Biotherapeutics made up ﹤0.01% of Wells Fargo's portfolio in Q2 2026, its #5285 holding.
  • Wells Fargo first reported a position in SAB Biotherapeutics in Q2 2022 and has held it in 9 quarters since.
  • 87 funds tracked by Wall St. Rank held SAB Biotherapeutics as of Q2 2026.

Based on Wells Fargo's 13F filing for Q2 2026, filed 14 Aug 2026.